Bard Lounge, 1st floor Bard Hall, 50 Haven Ave, New York, NY 10032
Dr. Baras serves as Vice President and Co-Head of the RGC, a fully integrated program spanning large-scale sequencing, analysis, and translational capabilities facilitating the advancement of Regeneron’s pipeline of therapeutics. He helped established numerous collaborations, such as with the Geisinger Health System to enroll and sequence at least 250,000 participants. The RGC’s research program has produced important new findings identifying new drug targets, supporting existing therapeutic programs, and contributing important new gene discoveries. To date, samples from over 100,000 participants have been sequenced at the RGC across dozens of ongoing projects and collaborations. Previously, Dr. Baras held roles and responsibilities at Regeneron across R&D and business development. Prior to Regeneron, Dr. Baras contributed to other biotechnology ventures and conducted research spanning cancer immunotherapies, nanotechnology, respiratory drug development, and other areas. Dr. Baras received his Bachelor’s of Science, M.D., and M.B.A., all from Duke University.